- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
39 result(s) found for: Eplerenone.
Displaying page 1 of 2.
EudraCT Number: 2013-000189-12 | Sponsor Protocol Number: ABR43234 | Start Date*: 2013-03-14 |
Sponsor Name:University Medical Centre Nijmegen | ||
Full Title: Effects of the selective mineralocorticoid receptor antagonist eplerenone on extracellular formation of adenosine | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002175-34 | Sponsor Protocol Number: EPOCH | Start Date*: 2012-10-23 |
Sponsor Name:Med. Univ. Wien, Universitätsklinik f. Innere Medizin III, Abt. f. Nephrologie und Dialyse | ||
Full Title: Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients with Hypertension (EPOCH) | ||
Medical condition: proteinuric patients suffering from chronic kidney disease (II - III) ,diabetes mellitus II and hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004809-58 | Sponsor Protocol Number: HEBRO-001 | Start Date*: 2019-04-04 | |||||||||||
Sponsor Name:Institute for study, research, education and therapy of vascular, heart, brain and kidney nosologies (I.N.A.K.E.N) | |||||||||||||
Full Title: Comparative study of eplerenone-based treatment strategy versus irbesartan-based blood pressure lowering in obese hypertensive patients (HEBRO Study) | |||||||||||||
Medical condition: Primary Hypertension and Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006123-37 | Sponsor Protocol Number: SI-C-019 | Start Date*: 2012-06-06 | |||||||||||
Sponsor Name:Solvotrin Innovations Ltd | |||||||||||||
Full Title: Impact of Eplerenone on Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetic Patients | |||||||||||||
Medical condition: Asymptomatic left ventricular diastolic dysfunction in diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022308-34 | Sponsor Protocol Number: JW/IB/AG | Start Date*: 2011-04-19 | ||||||||||||||||
Sponsor Name:Central Manchester Foundation Hospitals Trust | ||||||||||||||||||
Full Title: Eplerenone in Metabolic Syndrome: An investigation into the effects of Eplerenone on perivascular adipose tissue and small artery tone in obesity | ||||||||||||||||||
Medical condition: Obesity and Metabolic Syndrome (combination of obesity, hypertension, raised blood glucose and cholesterol abnormalities) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004641-25 | Sponsor Protocol Number: 201700823 | Start Date*: 2019-04-30 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation. | ||
Medical condition: Proteinuric Kidney disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002168-17 | Sponsor Protocol Number: BAY94-8862/16275 | Start Date*: 2015-12-09 | |||||||||||||||||||||||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||||||||||||||||||||||
Full Title: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in... | |||||||||||||||||||||||||||||||||
Medical condition: Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002119-17 | Sponsor Protocol Number: EPLERAF-01 | Start Date*: 2008-02-15 | |||||||||||
Sponsor Name:Universität des Saarlandes | |||||||||||||
Full Title: EPLERAF-Studie: Eplerenon in der Prävention von Vorhofflimmer-Rezidiven nach Kardioversion / [EPLERAF-Study: Eplerenone in the prevention of atrial fibrillation recurrences after cardioversion] | |||||||||||||
Medical condition: Recurrence of atrial fibrillation after electrical cardioversion of persistent atrial fibrillation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004119-11 | Sponsor Protocol Number: SPECT | Start Date*: 2016-12-19 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Study on half-dose Photodynamic therapy versus Eplerenone in chronic CenTRAl serous chorioretinopathy (SPECTRA trial) | |||||||||||||
Medical condition: Chronic central serous chorioretinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002019-16 | Sponsor Protocol Number: U-2015-030 | Start Date*: 2016-09-06 | |||||||||||
Sponsor Name:Uppsala Clinical Research center | |||||||||||||
Full Title: Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction | |||||||||||||
Medical condition: Heart Failure with Preserved Ejection Fraction, HFPEF | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005683-21 | Sponsor Protocol Number: ENM-EA-030 | Start Date*: 2012-10-09 |
Sponsor Name:Medizinische Universität Graz | ||
Full Title: Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial | ||
Medical condition: Primary hyperparathyroidism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005407-24 | Sponsor Protocol Number: KKIKEM | Start Date*: 2015-02-27 |
Sponsor Name:IKEM | ||
Full Title: Effect of early administration of eplerenone in patients after acute myocardial infarction | ||
Medical condition: Verify the efficacy of early administration of eplerenone in relation to the development of pathological remodeling of the myocardium in patients after myocardial infarction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000113-70 | Sponsor Protocol Number: NA | Start Date*: 2016-04-30 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: Clinical efficacy and mechanistic evaluation of Eplerenone for Central serous chorio-retinopathy – the VICI randomised trial. | |||||||||||||
Medical condition: Central serous chorio-retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004689-42 | Sponsor Protocol Number: RGHT000298 | Start Date*: 2008-07-29 |
Sponsor Name:Belfast Health and Social Care Trust | ||
Full Title: Insulin action and hypertension: effects of hyperaldosteronism and its treatment. | ||
Medical condition: The effect of eplerenone on insulin action is being studied in patients with mild essential hypertension. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004399-35 | Sponsor Protocol Number: Pfi-RW-2005-01 | Start Date*: 2005-01-18 |
Sponsor Name:North Glasgow Trust | ||
Full Title: The effects of eplerenone on left ventricular remodelling post-acute myocardial infarction: a double-blind placebo-controlled cardiac MR-based study. | ||
Medical condition: Post-myocardial infarction left ventricular dysfunction, in the absence of heart failure - clinical (i.e. Killip III or IV) or radiological - nor established diabetes mellitus. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002627-15 | Sponsor Protocol Number: BAY94-8862/14564 | Start Date*: 2013-05-27 | |||||||||||||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||||||||||||
Full Title: A randomized, double-blind, double-dummy, multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart ... | |||||||||||||||||||||||
Medical condition: Subjects with worsening chronic heart failure (WCHF) and left ventricular systolic dysfunction and either type 2 diabetes mellitus (DM type 2) with or without chronic kidney disease (CKD) or modera... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FI (Completed) AT (Completed) SE (Completed) LT (Completed) DE (Completed) HU (Completed) CZ (Completed) NO (Completed) NL (Completed) PT (Completed) DK (Completed) IT (Completed) ES (Completed) BG (Completed) GR (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-018639-17 | Sponsor Protocol Number: UR2010MSyn | Start Date*: 2010-06-29 | |||||||||||
Sponsor Name:University Hospital Erlangen | |||||||||||||
Full Title: Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with met... | |||||||||||||
Medical condition: Metabolic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001067-23 | Sponsor Protocol Number: i-PHORECAST | Start Date*: 2014-02-10 | |||||||||||
Sponsor Name:University Medical Centre Groningen | |||||||||||||
Full Title: PHOspholamban RElated CArdiomyopathy STudy - intervention (i-PHORECAST) | |||||||||||||
Medical condition: Phospholamban-related Cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003662-14 | Sponsor Protocol Number: GN17CA082 | Start Date*: 2019-05-13 | |||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde [...] | |||||||||||||
Full Title: Patiromer-facilitated, dose-escalation of mineralocorticoid antagonists for the management of worsening congestion in people with heart failure and hyperkalaemia. A Phase IV, registry-based, rand... | |||||||||||||
Medical condition: People with heart failure, worsening symptoms and signs of congestion and serum potassium >5mmol/L | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002519-14 | Sponsor Protocol Number: 2015-775 | Start Date*: 2015-08-25 | |||||||||||
Sponsor Name:Herlev Hospital | |||||||||||||
Full Title: The MIRAD study - Mineralocorticoid Receptor Antagonists in Type 2 Diabetes. A randomised, double-blind, placebo-controlled study of the effect of Mineralocorticoid Receptor Antagonists in Type 2 D... | |||||||||||||
Medical condition: diabetes (type 2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.